Expression of burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells

Authors

  • L. J. Murray,

    1. Imperial Cancer Research Fund Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London ECIA 7BE
    Current affiliation:
    1. Division of Immunology, National Institute of Medical Research, The Ridgeway, Mill Hill, London NW7 1AA. UK
    Search for more papers by this author
  • J. A. Habeshaw,

    1. Laboratoire d'lmmunobiologie des Tumeurs, CNRS LA 207, Institut GustaveRoussy, Rue Camille Desmoulins, 94800 Villejuif, France
    Search for more papers by this author
  • J. Wiels,

    1. Imperial Cancer Research Fund Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London ECIA 7BE
    Search for more papers by this author
  • M. F. Greaves

    1. Leukaemia Research Fund Centre at the Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK
    Search for more papers by this author

Abstract

Monoclonal antibody 38.13 was raised against the Burkitt lymphoma cell line Daudi and has been previously shown to recognize a globotriaosylceramide (pk) determinant expressed selectively on Burkitt and a few other B-cell lymphomas. We report here that 38.13 binds to a subset of normal B lymphocytes in germinal centres of secondary lymphoid follicles as well as to blood vessels. In malignant populations equivalent to various developmental compartments of the B-cell lineage, only those with a follicular phenotype express the pk determinant at detectable levels. The expression of this tumour-associated antigen, in common with many others, is therefore regulated in concert with cell lineage and maturation status.

Ancillary